Journal Mobile Options
Table of Contents
Vol. 3, No. 3, 2011
Issue release date: September – December
Section title: Published: December 2011

Open Access Gateway

Case Rep Dermatol 2011;3:259–262
(DOI:10.1159/000334833)

Bullous Variant of Sweet’s Syndrome after Herpes Zoster Virus Infection

Endo Y. · Tanioka M. · Tanizaki H. · Mori M. · Kawabata H. · Miyachi Y.
Departments of aDermatology and bHematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Abstract

Aim: Cutaneous manifestations of Sweet’s syndrome (SS) are typically painful plaque-forming erythematous papules, while bullae are quite uncommon. We present a case of bullous variant of SS in acute myeloid leukaemia. In this case, herpes infection of the left mandible had preceded the development of SS. Case Report: A 75-year-old male with myelodysplastic syndrome first presented with herpes zoster virus infection-like bullae and erosive plaques on the left side of the face and neck. Treatment with valacyclovir and antibiotics was effective only for the initial lesions, whereas the other bullae kept developing predominantly on the left side. Histopathological study revealed epidermal bulla formation, pandermal neutrophilic infiltration, erythrocyte extravasation and subepidermal oedema, but no vasculitis. The findings suggested the diagnosis of bullous variant of SS. Discussion: Our case was unique in that bullous SS symptoms developed predominantly on one side of the cheek and neck where the herpes zoster infection occurred prior to SS. The tendency may explain the possible association between viral infection and development of SS.


  

Author Contacts

Yuichiro Endo, MD
Department of Dermatology, Kyoto University
54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507 (Japan)
Tel. +81 75 751 3310, E-Mail yendou-tky@umin.ac.jp

  

Article Information

Published online: December 2, 2011
Number of Print Pages : 4
Number of Figures : 3,

  

Publication Details

Case Reports in Dermatology

Vol. 3, No. 3, Year 2011 (Cover Date: September - December)

Journal Editor: Jemec G.B.E. (Roskilde)
ISSN: NIL (Print), eISSN: 1662-6567 (Online)

For additional information: http://www.karger.com/CDE


Article / Publication Details

First-Page Preview
Abstract of Published: December 2011

Published online: 12/2/2011

Number of Print Pages: 4
Number of Figures: 3
Number of Tables: 0

ISSN: (Print)
eISSN: 1662-6567 (Online)

For additional information: http://www.karger.com/CDE


Open Access License / Drug Dosage

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.